NasdaqGS:BMRNBiotechs
Does BioMarin (BMRN) Expanding Into ReNU Syndrome Refine Its Rare Disease Pipeline Strategy?
Earlier this week, n-Lorem Foundation announced an early-stage research collaboration and exclusive global licence agreement with BioMarin Pharmaceutical to develop an investigational antisense oligonucleotide therapy for ReNU syndrome, with preclinical work underway and plans for future clinical studies.
A key aspect of the deal is BioMarin’s intention to develop the medicine for broader use across the ReNU syndrome community, aiming to address an estimated 75% of cases and potentially...